Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  
Google
Web www.equitybulls.com
Stock Report

| More

European Medicines Agency grants Orphan Drug Designation to Saroglitazar Mg for the treatment of patients with Primary Biliary Cholangitis

Posted On: 2021-07-21 06:52:22 (Time Zone: UTC)


Zydus, a leading discovery-based, global pharmaceutical company, today announced that European Medicines Agency (EMA) has granted 'Orphan Drug Designation' (ODD) to Saroglitazar Mg for the treatment of patients with Primary Biliary Cholangitis (PBC).

Orphan drug status in Europe is given to medicines with the potential to be safe and effective treatments for rare, life-threatening, or chronically debilitating conditions affecting no more than 5 people in 10,000 people. It provides companies with a range of incentives, including assistance with trial protocols, reduced regulatory fees, differentiated evaluation procedures for Health Technology Assessments in certain countries, access to a centralized marketing authorization procedure valid in all EU Member States, and a 10-year period of market exclusivity if the treatment eventually is approved.

Earlier, the USFDA has granted 'Orphan Drug Designation' and 'Fast Track Designation' to Saroglitazar Mg for PBC.

Saroglitazar Mg is a potent and selective peroxisome proliferator-activated receptor alpha and gamma dual agonist. Results of PHASE 2, prospective multicentre randomized doubleblind, placebo controlled study to evaluate the safety, tolerability and efficacy of Saroglitazar Mg in patients with PRIMARY BILIARY CHOLANGITIS (EPICS) was presented earlier at the Liver Meeting® 2020, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) [ClinicalTrials.gov Identifier: NCT03112681]. The treatment options are still evolving for PBC and Saroglitazar holds immense potential based on its safety and efficacy profile so far. The global market for PBC treatment is expected to grow at a CAGR of 36.3% from 2018 - 2026 and is expected to reach USD 10.8 bn by 2026 as per Coherent market insights.

Speaking on the development, Pankaj R. Patel, Chairman, Zydus Group said, "We are pleased that the EMA has granted an Orphan Drug Designation to Saroglitazar Mg for the treatment of Primary Biliary Cholangitis (PBC). This is a serious health condition and we are committed in our clinical development efforts to improve the quality of life of patients suffering from PBC with a safe and efficacious treatment."

Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.622.75 as compared to the previous close of Rs. 639.5. The total number of shares traded during the day was 263809 in over 5918 trades.

The stock hit an intraday high of Rs. 639.55 and intraday low of 615. The net turnover during the day was Rs. 164729140.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com


Other Headlines:

Rain Carbon Opens State-of-the-Art Rubber Lab at Distillation and Advanced Materials Facility in Germany

Alembic Pharmaceuticals announces USFDA Final Approval for Clomipramine Hydrochloride Capsules USP; 25 mg, 50 mg, and 75 mg

IPCA Laboratories Ltd Q1FY22 consolidated net profit rises QoQ to Rs. 306.66 crores

TTK Healthcare Ltd Q1FY22 PAT drops QoQ to Rs. 5.99 crore

Caplin Point Laboratories Ltd Q1FY22 consolidated PAT at Rs. 70.85 crore

Kunstoffe Industries Ltd Q1FY22 net profit at Rs. 36.11 lakhs

Cera Sanitaryware Ltd posts Q1FY22 consolidated PAT of Rs. 12.20 crore

S V Global Mill Ltd Q1FY22 consolidated PAT at Rs. 17.61 lakhs

Aurionpro announces successful go-live of the project in Transit Business

Imagicaaworld launches Virtual Queuing App for Entertainment Parks

JSPL's Steel Sales rise 21% MoM in July 21

Indian Energy Exchange Ltd - July 2021 operating highlights

Aurionpro announces the launch of cloud based Lending Platforms

CESC's subsidiary emerges highest bidder for power distribution in Chandigarh

The Indigenous Aircraft Carrier (IAC) - 'Vikrant' proceeds for maiden sea trial

Novelis Reports First Quarter Fiscal 2022 Results

Nava Bharat Ventures Ltd reports consolidated PAT of Rs. 45.44 crores in Q1FY22

Thomas Cook India Ltd Q1FY22 consolidated loss at Rs. 83.43 crore

Tata Power-DDL empowers the residents of North Delhi's JJ cluster area

Tata Steel's West Bokaro Division onboards 16 women Heavy Earth Moving Machinery operators in a pathbreaking initiative

MitraClip implant at Apollo Hospitals saves 41-year-old farmer who waited 91 days for a heart transplant!

IndiGo celebrates its 15th Anniversary with special fares starting INR 915

Dr. Reddy's Laboratories announces sale of its U.S. and Canada territory rights for EL YXYB (celecoxib oral solution) 25 mg/ml

Reliance Industries Doubling PET recycling capacity

100+ Global Enterprises Take Advantage of Infosys Living Labs to Accelerate their Digital Innovation Agenda

Time Technoplast Ltd receives trial order from OMCs for Type-IV LPG composite cylinders

Blue Chip Tex Industries Limited board recommends dividend of Rs. 3

The Investment Trust of India Ltd Q1FY22 consolidated PAT at Rs. 62.93 lakhs

PDS Multinational Fashions Limited posts Rs. 53.89 crore consolidated PAT in Q1FY22

National Plastic Technologies Ltd Q1 FY2021-22 net profit at Rs. 99.66 lakhs

T T Ltd Q1FY22 PAT surges to Rs. 4.15 crore

Telesys Info-Infra India Ltd Q1FY22 net profit falls to Rs. 41.66 lakhs

Leading Leasing Finance and Investment Co. Ltd Q1FY22 net profit at Rs. 9.59 lakhs

Tasty Bite Eatables Ltd Q1FY22 PAT declines QoQ to Rs. 7.16 crore

Adani Total Gas Ltd Q1FY22 consolidated net profit at Rs. 142.58 crores

Cosmo Films Ltd reports rise in consolidated PAT to Rs. 86.72 crore during Q1FY22

Asahi Songwon Colors Ltd posts lower Q1FY22 consolidated PAT of Rs. 4.55 crore

APM Finvest Ltd Q1FY22 net profit at Rs. 5.83 crore

Tata Communications Ltd Q1FY22 consolidated net profit at Rs. 296.11 crores

HPCL Q1FY22 consolidated net profit slips to Rs. 2003.90 crores

Ion Exchange India Limited bags order from Indian Oil Corporation Ltd

Greenply forays into MDF business, to setup 800 CBM per day capacity plant in Gujarat

Lyka Labs Limited announces Q1FY22 results

TCS Named a Leader in Veeva Services by Everest Group

UTI Mutual Fund launches 'UTI Focused Equity Fund'

Shetron Ltd Q1FY22 net profit at Rs. 1.04 crore

Ikab Securities and Investment Ltd reports net profit of Rs. 91.40 lakhs in Q1FY22

Artemis Electricals Ltd posts PAT of Rs. 13.75 lakhs in Q1FY22

Machino Plastics Ltd Q1FY22 loss at Rs. 2.44 crore

Apollo Tyres Ltd reports consolidated PAT of Rs. 127.78 crore in Q1FY22


Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2020